Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease-Reference-Cited by-同舟云学术

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease

Published:2015-11-05 Issue:2 Volume:19 Page:138-148
ISSN:1386-341X
Container-title:Pituitary
language:en
Short-container-title:Pituitary

Author:

Fleseriu Maria,Pivonello Rosario,Young Jacques,Hamrahian Amir H.,Molitch Mark E.,Shimizu Chikara,Tanaka Tomoaki,Shimatsu Akira,White Tracy,Hilliard Annie,Tian Chuan,Sauter Nicholas,Biller Beverly MK,Bertagna Xavier

Funder

Novartis Pharma AG

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s11102-015-0692-z.pdf

Reference26 articles.

1. Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing’s syndrome. Lancet 386(9996):913–927

2. Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454–2462

3. Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing’s disease. Endocr Rev 36(4):385–486

4. Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A (2008) Cushing’s syndrome. Endocrinol Metab Clin N Am 37(1):135–149

5. Tritos NA, Biller BM, Swearingen B (2011) Management of Cushing disease. Nat Rev Endocrinol 7(5):279–289

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sleep disruption in patients with active and treated endogenous Cushing’s syndrome;Pituitary;2024-09-09

2. Treatment modalities and outcomes in pediatric Cushing’s disease – report of three cases and literature review;Journal of Pediatric Endocrinology and Metabolism;2024-05-27

3. Prolonged Adrenal Insufficiency After Osilodrostat Exposure With Eventual Recovery of Adrenal Function;JCEM Case Reports;2024-05-24

4. Current and Emerging Pharmacological Therapies for Cushing's Disease;Current Pharmaceutical Design;2024-03

5. A Case of an Ectopic ACTH-Producing Tumor With Adrenal Shrinkage During Osilodrostat Administration;JCEM Case Reports;2024-01-08